Search

Publications

Machado HE, Mitchell E, Øbro NF, Kübler K, Davies M, Leongamornlert D, Cull A, Maura F, Sanders MA, Cagan ATJ, McDonald C, Belmonte M, Shepherd MS, Vieira Braga FA, Osborne RJ, Mahbubani K, Martincorena I, Laurenti E, Green AR, Getz…

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of the EHA

During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.

Read more

EHA-TSH Hematology Tutorial

EHA is joining the Turkish Society of Hematology (TSH) to organize the EHA-TSH Hematology Tutorial on T Cell Lymphomas. Date: June 29-30, 2024
Location: Ankara, Türkiye
Format: In-Person

Target audienceHematology fellows from Türkiye.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2019

Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs: 
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)

EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…

Read more

GoCART coalition activities (CARTs and cellular therapies)

GoCART Clinical Case Discussion Series for Physicians - 4th edition
Panel: Dr. Sara Ghorashian, Dr. Peter Bader and Dr. Franco Locatelli along with moderator Dr.

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Program

All session times are in Eastern European Time (EET).

Read more

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more